18:28:30 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-09-22 Kvartalsrapport 2023-Q2
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020


ListaMERK Equities
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2021-05-28 13:37:56
OSLO/LONDON, May 28th 2021: EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster
Therapy (ACT®) across multiple therapeutic areas, today provided an update
regarding the ongoing phase I ACTIVATE study.

Enrolment of patients in the study at the Royal Marsden Hospital in London has
been adversely impacted through the Covid-19 pandemic period. There have been
seven patients enrolled in the study with five patients' data evaluable to date.
A number of valuable and encouraging insights have been gained from this first
cohort of treated patients, particularly with respect to application of

In addition, as the organisation has expanded with appointment of experienced
senior executives, focus has increased on improving quality management and
internal governance processes. As a consequence, robust internal governance
processes have been developed and implemented.

In parallel, a protocol amendment is planned with a consequent impact on patient
enrolment, which is anticipated to restart in Q4 2021.

This additional foundational work will provide a strong platform to evaluate the
exciting potential of Acoustic Cluster Therapy in oncology and other therapeutic

For more information contact:

EXACT Therapeutics
Dr Rafiq Hasan, CEO

Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
Tel: +44 (0) 203 922 1906
Email: Exact@optimumcomms.com

About EXACT-Tx
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com

About ACT®
o ACT® comprises a proprietary formulation consisting of microbubbles and
microdroplets that is activated through the application of ultrasound with the
consequent increase in targeted delivery of a co-administered therapeutic agent.

o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however, the ACT® platform has
potential across multiple therapeutic areas (infectious diseases, CNS,
immunotherapy) and classes of therapeutic agents.